Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.76
(-2.56%)
EUR 0.76
(-2.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.69 Million EUR | 649.48% |
| 2022 | 626.71 Thousand EUR | -18.23% |
| 2021 | 766.47 Thousand EUR | 148.85% |
| 2020 | 308 Thousand EUR | -64.96% |
| 2019 | 879 Thousand EUR | 32.53% |
| 2018 | 663.24 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.84 Million EUR | -18.08% |
| 2024 Q2 | 3.84 Million EUR | 0.0% |
| 2023 Q2 | 698.49 Thousand EUR | 151.84% |
| 2023 Q1 | 277.36 Thousand EUR | -55.74% |
| 2023 Q3 | 4.69 Million EUR | 572.46% |
| 2023 FY | 4.69 Million EUR | 649.48% |
| 2023 Q4 | 4.69 Million EUR | 0.0% |
| 2022 Q4 | 626.71 Thousand EUR | 51.96% |
| 2022 FY | 626.71 Thousand EUR | -18.23% |
| 2022 Q3 | 412.4 Thousand EUR | -71.46% |
| 2022 Q2 | 1.44 Million EUR | 183.68% |
| 2022 Q1 | 509.47 Thousand EUR | -33.53% |
| 2021 Q1 | 470.07 Thousand EUR | 52.44% |
| 2021 FY | 766.47 Thousand EUR | 148.85% |
| 2021 Q4 | 766.47 Thousand EUR | 109.62% |
| 2021 Q2 | 470.07 Thousand EUR | 0.0% |
| 2021 Q3 | 365.64 Thousand EUR | -22.22% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 308 Thousand EUR | -64.96% |
| 2020 Q3 | 297.12 Thousand EUR | 0.0% |
| 2020 Q4 | 308.37 Thousand EUR | 3.79% |
| 2019 FY | 879 Thousand EUR | 32.53% |
| 2018 FY | 663.24 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | 1.8 Million EUR | -160.603% |
| Philogen S.p.A. | 28.68 Million EUR | 83.623% |